Editorial Board ::: Current Radiopharmaceuticals

ISSN: 1874-4729 (Online)
ISSN: 1874-4710 (Print)


Volume 10, 3 Issues, 2017


Download PDF Flyer




Current Radiopharmaceuticals

This journal supports open access

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Sean L. Kitson
Department of Biocatalysis and Isotope Chemistry Almac Sciences
Almac House
Craigavon
Northern Ireland


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Editorial Board

Editor-in-Chief:

Sean L. Kitson (Biography
Sean L. Kitson

Dr Kitson is an Investigator of Radiochemistry at Almac, UK. He has over 15 years of experience in the synthesis of carbon-14 labelled compounds. Dr Kitson is the Editor-in-Chief of Current Radiopharmaceuticals published by Bentham Science Publishers and the Journal of Diagnostic Imaging in Therapy. He has published over 45 research, reviews and commercial articles in the area of carbon-14 synthesis and medical imaging. His contribution to radiochemistry was acknowledged by winning the 2006 Wiley Journal of Labelled Compounds and Radiopharmaceuticals Young Scientists Award. Since, 2007 he has been a Member of the Scientific Committee for the International Isotopes Society (IIS) UK group.

)

Department of Biocatalysis and Isotope Chemistry Almac Sciences
Almac House
Craigavon
Northern Ireland



Co-Editor:

Luigi Mansi
Interuniversity Research Centre on Sustainable Development (CIRPS)
Roma- Napoli
Italy


Associate Editors:

G.L. Cascini (Biography
G.L. Cascini

Prof. Cascini is nuclear medicine specialist with a PhD in diagnostic imaging obtained from the University of Naples. He worked as medical assistant in the National Cancer Institute and assistant professor in Catanzaro. Prof. Cascini actually is Associate Professor in Diagnostic Imaging and medical director of nuclear medicine unit in UMG of Catanzaro. He has published more than 60 scientific papers concerning the nuclear medicine in neurology and oncology.

)

University of Catanzaro
Catanzaro
Italy

F. Dollé (Biography
F. Dollé

Frédéric Dollé graduated from the University of Strasbourg, France, where he also completed his PhD in organic chemistry in 1991. End of 1993, he joined the Life Sciences Division of the French atomic energy commission (CEA) at the Service Hospitalier Frédéric Joliot (Orsay), where his research interests still focus on the development of novel radiotracers for in vivo molecular imaging using Positron Emission Tomography, as well as the development and application of novel methods for the synthesis of carbon-11- and fluorine-18-labelled probes. Co-author of over 200 publications, he is also associate-editor of Current Radiopharmaceuticals since 2010.

)

CEA, Institut des sciences du vivant Frédéric Joliot
Saclay
France

J. Kunikowska
Medical University of Warsaw
Warsaw
Poland

A. Ciarmiello
S. Andrea Hospital
La Spezia
Italy

P.A. Erba
University of Pisa Medical School
Pisa
Italy

M. Marengo (Biography
M. Marengo

Born in Bologna (Italy) January 19, 1956. Director of the Medical Physics Department at the S.Orsola – Malpighi University Hospital, Bologna (Italy). MSc in Physics and PhD in Medical Physics from the University of Bologna, has a long experience the field of Nuclear Medicine Physics; he contributed to the planning of the PET Centre of the S.Orsola – Malpighi University Hospital. From 1990 is appointed as Professor of Nuclear Medicine Physics at the Medical School of the University of Bologna. He is a Technical expert for the International Atomic Energy Agency and consultant expert of the European Medicines Agency for radiopharmaceutical products.

)

University of Bologna
Bologna
Italy

V. Cuccurullo (Biography
V. Cuccurullo

Dr. Vincenzo Cuccurullo was born in Naples, Italy; M.D. degree from the Second University of Naples in 1994 and in 1998 Specialist in Nuclear Medicine. In 2002, he was awarded a Ph.D. in Diagnostic Imaging. Since 2003, Dr. Cuccurullo has been working as a Medical Doctor in Nuclear Medicine at the Second University of Naples and from 2008 as an Assistant Professor in Nuclear Medicine researching in Diagnostic Imaging techniques. Author of more of 200 articles consisting of research papers, abstracts and chapters of books, invited speaker at national and international meetings and workshops, book reviewer for the European J. of Nuclear Medicine and Molecular Imaging and Associate Editor of Current Radiopharmaceuticals.

)

Second University of Naples
Naples
Italy

L. Evangelista
Radiotherapy and Nuclear Medicine Unit
Padova
Italy

D. Piciu
Institute of Oncology "Prof.Dr.Ion Chiricuta"
Cluj-Napoca
Romania


Regional Editors:

U. Ackermann
Austin Health, Heidelberg
Narre Warren
Australia

J. Cerci
Quanta Diagnóstico e Terapia
Curitiba
Brasil

N. Avril
University Hospitals Case Medical Center
Cleveland
OH
USA

R. N. Krasikova
N.P. Bechtereva Institute of the Human Brain
Saint Petersburg
Russia

S. Balogova (Biography
S. Balogova

Assoc. Prof. Sona Balogova graduated at Comenius University in Bratislava and started working at nuclear medicine department of University Hospital of Bratislava. At present is full time employed as a professor of nuclear medicine and head of department of nuclear medicine of Comenius University and St. Elisabeth oncology institute in Bratislava. Scientific interest is focused on innovative clinical applications of approved radiopharmaceuticals and on clinical applications and approval of non-FDG radiopharmaceuticals.

)

Comenius University & St Elisabeth oncologic institute
Bratislava
Slovakia

V. Rangarajan (Biography
V. Rangarajan

Dr V Rangarajan has more than twenty-five years’ experience in clinical Nuclear Medicine and is the Professor & Head of the Department of Nuclear Medicine & Molecular Imaging at the Tata Memorial Centre, Mumbai, India. The centre is affiliated to the Homi Bhabha National Institute (Deemed University) He has authored more than 200 articles, eight chapters and one Technical document.

)

Tata Memorial Centre
Mumbai
India


Editorial Board Members:

F. Aigbirhio
University of Cambridge
Cambridge
UK

F. Bertagna
University of Brescia
Brescia
Italy

R.T. Brown
Almac Sciences
Craigavon
Northern Ireland

M. Chinol
European Institute of Oncology
Milano
Italy

A. Duatti
International Atomic Energy Agency
Vienna
Austria

P.K. Garg
Wake Forest University Health Sciences
Winston Salem, NC
USA

V. Gottumukkala
Eckert & Ziegler Eurotope
Hopkinton, MA
USA

C. Halldin
Karolinska Institutet
Stockholm
Sweden

A.G. Horti
Johns Hopkins University
Baltimore, MD
USA

K. Kairemo
International Comprehensive Cancer Center Docrates
Helsinki
Finland

F.F. (Russ) Knapp (Biography
F.F. (Russ) Knapp

Dr. Russ Knapp is internationally recognized for development of diagnostic and therapeutic radiopharmaceuticals and directed the Nuclear Medicine Program at ORNL from 1977-2012. Editorial Board appointments have included the Journal of Nuclear Medicine, European Journal of Nuclear Medicine, Applied Radiation and Isotopes, World Journal of Nuclear Medicine and Current Molecular Imaging . He has authored over 400 journal articles, book chapters and Proceedings. In 1991-1992 and again in 2015, he conducted research at the Clinic for Nuclear Medicine, in Bonn, Germany, supported as a Senior American Scientist of the Alexander von Humboldt Foundation. He is recognized for his translational clinical introduction of iodine-123-BMIPP for cardiac imaging and rhenium-188 for targeted therapy.

)

Emeritus Corporate Research Fellow
Oak Ridge National Laboratory (ORNL)
Oak Ridge, NT
USA

P. Kumar
Department of Oncology, University of Alberta
Edmonton, AB T6G 1Z2
Canada

J-H. Lee (Biography
J-H. Lee

Dr. Jaeho Lee has received his PhD in the University of Maryland, College Park. Currently, he is working as a staff scientist in the National Institutes of Health, USA. His research has included Nanomedicine (e.g., stem cell labeling and drug delivery with liposome), Radiopharmaceuticals (e.g., Tc-99m liposome, antibody radiolabeling with radioisotopes such as In-111, Zr-89, Y-90, and Cu-64 for clinical trials and animal studies) and cancer therapy development with radiolabeled antibodies and computer simulation models. He is serving as an editorial member of several reputed journals like Current Radiopharamaceuticals, Journal of Radiology & Radiation Therapy, and Journal of Nanomedicine and Biotherapuetic Discovery. He has authored 19 research articles.

)

National Institutes of Health
Maryland
USA

B. Långström
Uppsala University
Imanet
Sweden

J.M. Marti-Climent
Clínica Universidad de Navarra
Pamplona
Spain

R. Neelamegam
Massachusetts General Hospital/Harvard Medical School
MA
USA

J.P. Pouget (Biography
J.P. Pouget

Dr Jean-Pierre Pouget obtained his PhD thesis in Radiobiology in 2000 from the Curie Institute in Paris and carried-out a post-doctoral fellowship in the Nuclear Medicine Research Laboratory at Barts and the London School of Medicine and Dentistry. He then moved to Paris to the French Radiation Protection and Nuclear Safety Agency (IRSN) for 4 years where he worked on radiation casualties. After moving to Montpellier, he joined the French National Institute for Health and Medical research (INSERM) where he is now leader of the Radiobiology and Targeted Radiotherapy team at the Cancer Research Institute of Montpellier (INSERM, France). He develops new radiopharmaceuticals for cancer imaging and therapy with a special focus on radiobiology. He has published about 50 papers dealing with radiobiology and radionuclide therapy and several patents. Besides research activity, Dr Pouget is involved in teaching at the University of Montpellier.

)

IRCM
Montpellier
France

D. Roeda
Service Hospitalier Frédéric Joliot
Orsay
France

D.J. Schlyer
Brookhaven National Laboratory
Upton, NY
USA

S.V. Smith
CAMS
ANSTO, Sydney
Australia

A.C. Spivey (Biography
A.C. Spivey

Alan Spivey (http://www.imperial.ac.uk/people/a.c.spivey) has been professor of synthetic chemistry at Imperial College London since 2008. Previously, he was a lecturer then reader in the Department of Chemistry, University of Sheffield. His research encompasses the development of new reactions, synthesis of complex molecules of biomedical interest, chemical biology, medicinal chemistry including interests in PET tracers for cancer diagnosis and monitoring. omputer aided drug design (CAD), solid phase synthesis and imaging chemistry. For further details of his groups research activities see: http://www.imperial.ac.uk/spiveygroup.

)

Imperial College London
London
UK

H. Tian (Biography
H. Tian

Dr. Haibin Tian is assistant member and director of PET Radiochemistry at Moffitt Cancer Center. He is Radiochemist with over 10 years of experience in the investigating novel PET radiopharmaceutical in cancer imaging and has been at the forefront of IDO target PET imaging in immunotherapy. Dr. Tian holds a Ph.D. in Radiochemistry from The Chinese Academy of Sciences, Dr. Tian has authored more than 30 manuscripts, 5 patents, and service as Editorial Board member over 6 journal. Dr. Tian is also an adjunct faculty member at University of South Florida medical school.

)

University of South Florida
Tampa, FL
USA

J-L. Vanderheyden
GE Healthcare Life Sciences
Waukesha, WI
USA

N. Belcari (Biography
N. Belcari

Nicola Belcari received his PhD in Applied Physics from the University of Pisa in 2003. Since 2007 he is atf the Department of Physics of the University of Pisa and since 2016 he is Associate Professor in Medical Physics. His present research is oriented to the development of multi-modality instrumentation for high-resolution pre-clinical PET/CT and brain-dedicated PET/MRI systems. He is also an expert of performance assessment of pre-clinical PET/CT instrumentation.

)

University of Pisa and INFN Pisa
Pisa
Italy

P. Blower
King’s College London
London
UK

M. Chianelli
Regina Apostolorum Hospital
Albano
Italy

O. T. DeJesus
University of Wisconsin School of Medicine and Public Health
Madison
USA

S. Fanti (Biography
S. Fanti

Prof. Stefano Fanti graduated at University of Bologna. Started working in conventional nuclear medicine in the ’90, then involved in the project of PET Unit at S.Orsola Policlinic Hospital, participating to site planning then appointed as medical director in 2002. The PET Unit at S.Orsola is now recognized as one of the most active in Europe; in particular known for the nonFDG scans, in both clinical routine and research area. At present he is full time employed in Nuclear Medicine as Professor of Diagnostic Imaging as well as Director of Nuclear Medicine Division at the S.Orsola Hospital in Bologna. Author of more than 320 full articles published in peer reviewed international journals, several books and chapters; invited lecturer at more than 120 national and international meetings.

)

University of Bologna
Bologna
Italy

V. Garibotto (Biography
V. Garibotto

Dr. Valentina Garibotto is senior physician and lecturer at the Geneva University and Geneva University Hospital, with a main research interest in molecular imaging of neurodegenerative diseases. She obtained her doctorate (MD) in Medicine from the Genoa University Hopspital, her specialization in nuclear medicine in the San Raffaele Hospital and Bicocca University in Milan and the title of Privat Docent from the Geneva University. She has authored 85 peer reviewed articles (H index: 17) in the fields of clinical neuroimaging and nuclear medicine. She is member of the Neuroimaging Committee of the European Association of Nuclear Medicine.

)

Geneva University and Geneva University Hospitals
Geneva
Switzerland

L. Guerra (Biography
L. Guerra

Dr. Guerra is the clinical director of the PET/CT Unit at San Gerardo Hospital – University of Milano Bicocca - Monza (Italy). He has over 10 years of experience in PET/CT in oncology. He is currently focused on PET/CT in Lymphoma, particularly in Hodgkin lymphoma, DLBCL and follicular lymphoma. He participate to the PET/CT commission of the Fondazione Italiana Linfomi and to the Oncological Working Group for oncohematology of the Associazione Italiana di Medicina Nucleare (AIMN). He is also interested in PET/CT respiratory gating technique both in diagnosis and in radiotherapy planning of the tumors of lung, pancreas and liver. He has published many papers, mostly in oncologic PET/CT.

)

San Gerardo Hospital, University of Milano Bicocca
Monza
Italy

G. Hao (Biography
G. Hao

Dr. Hao obtained his Ph.D. in radiopharmaceutical chemistry from Beijing Normal University, China. He has over 15 years of experiences in the field of molecular imaging and radiochemistry to develop novel molecular imaging probes to diagnose and/or treat cancerous and cardiovascular diseases. Currently, Dr. Hao is an Assistant Professor in Department of Radiology and serves the Cyclotron and Radiochemistry Program as Research Radiochemist at UT Southwestern Medical Center in Texas. He has authored more than thirty peer-reviewed publications.

)

UT Southwestern Medical Center
TX
USA

H. Huang
Yale University
New Haven, CT
USA

M. Kassiou
University of Sydney
Camperdown
Australia

G.M. Knudsen (Biography
G.M. Knudsen

Gitte Moos Knudsen, MD, DMSc, is a translational neurobiologist and clinical neurologist with interest in advanced methodological developments that she subsequently applies in her research to address pertinent neurobiological and clinical issues. MD from the UnivCopenhagen, Denmark, trained neurologist at Rigshospitalet, Copenhagen, at laboratories in Bonn, Germany and at NIH, Maryland and Stony Brook, USA. Full professor of neurobiology at UnivCopenhagen in 1999. Since 2004 leader of the Neurobiology Research Unit at Rigshospitalet and currently Director for Center for Integrated Molecular Brain Imaging (www.Cimbi.org) and Center for Experimental Medicine Neuropharmacology (www.NeuroPharm.eu). She has an outstanding record of publications (>320) with an H-index of 52 (Google Scholar).

)

Copenhagen University Hospital
Copenhagen
Denmark

K-J. Langen (Biography
K-J. Langen

"Dr. Karl-Josef Langen is nuclear medicine physician focused on preclinical and clinical testing of new radiopharmaceuticals for nuclear medicine diagnostics. He qualified at RWTH Aachen university clinic in 1985 and completed training in nuclear medicine at the University of Düsseldorf in 1989. After habilitation in nuclear medicine in 1992 he became head of a research group at the Research Center Jülich (FZJ) focusing on SPECT/PET and correlative MR-PET imaging of brain tumors including Hybrid-PET-MRI. He was appointed professor and senior physician of the Department of Clinical and Experimental Nuclear Medicine at the RWTH Aachen University at the FZJ in 2013."

)

Forschungszentrum Jülich
Jülich
Germany

J.S. Lewis (Biography
J.S. Lewis

Professor Lewis currently serves as Vice Chair for Research and Chief of the Radiochemistry & Imaging Sciences Service in Memorial Sloan Kettering’s Department of Radiology, and as Director of Memorial Sloan Kettering’s Radiochemistry and Molecular Imaging Probe Core Facility. He is a Member in Memorial Sloan Kettering, head of a laboratory in the Sloan Kettering Institute’s Molecular Pharmacology Program, and a Professor at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences and at the Weill Cornell Medical College.

)

Memorial Sloan-Kettering Cancer Center
NY
USA

A. Mahmood
Harvard Medical School
Boston, MA
USA

P.M. Mitrasinovic
University of Belgrade
Belgrade
Yugoslavia

V.W. Pike (Biography
V.W. Pike

Dr. Pike is Chief of the PET Radiopharmaceutical Sciences Section of the Molecular Imaging Branch in the National Institute of Mental Health. He has nearly 40 years of experience in research on developing PET radiotracers, mainly for brain imaging. Previously, Dr. Pike served as the Head of Chemistry and Engineering at the MRC Cyclotron Unit (Imperial College). Dr. Pike has co-authored more than 300 peer-reviewed papers in his field.

)

National Institute of Mental Health
Bethesda, MD
USA

N. Ramamoorthy
International Atomic Energy Agency
Vienna
Austria

T.J. Ruth
University of British Columbia & TRIUMF
Vancouver, BC
Canada

P. Scott (Biography
P. Scott

Dr. Peter Scott is an Assistant Professor of Radiology at the University of Michigan, as well as Director of the PET Center and a Member of the Interdepartmental Program in Medicinal Chemistry. Scott’s group is involved in all aspects of Radiopharmaceutical Sciences including i) developing new methods for radiolabeling bioactive molecules, ii) design and synthesis of new radiotracers for PET imaging of CNS disorders such as Alzheimer’s disease, and iii) cGMP radiopharmaceutical manufacture. The goals of his lab are to use PET radiotracers to improve the understanding of disease mechanisms and, ultimately, employ them as companion diagnostics to support therapeutic development.

)

University of Michigan Medical School
MI
USA

M. Spadafora
S.G. Moscati Hospital
Avellino
Italy

J. Steinbach
Forschungszentrum Dresden-Rossendorf
Dresden
Germany

G. Treglia
Oncology Institute of Southern Switzerland
Bellinzona
Switzerland

A.D. Windhorst
VU University Medical Center
Amsterdam
The Netherlands

K. Bergström (Biography
K. Bergström

Dr. Bergström is a Chief Radiochemist at Helsinki University Central Hospital. He has 20+ years of experience in research developing molecular imaging tracers and methods. In 2007-2010, he served as CEO of Imanext Ltd, a CRO company specializing in molecular imaging. Before that he worked as R&D Director at MAP Medical Technologies Oy during. Prior to this he served as Vice Chief Chemist at Kuopio University Hospital. Dr. Bergström has obtained international research experience as a post-doctoral fellow (Dept. of Neuropsychiatric Research, Karolinska Hospital, Stockholm). Dr. Bergström’s publication list consists of more than 120 peer-reviewed scientific publications. He has received scientific awards such as Timo Heiskanen Prize, Finnish Society of Nuclear Medicine and Finnish Society of Radiology (2001) and CIS Jean Debiesse Award “Nuclear Medicine”, European Association of Nuclear Medicine (1995).

)

University of Helsinki
Helsinki
Finland

S. Boschi
S.Orsola-Malpighi University Hospital
Bologna
Italy

B.B. Chin (Biography
B.B. Chin

Dr. Chin is the Director of the Small Animal Translational PET / CT center at Duke University. He has over 20 years of research experience in radionuclide and molecular imaging. Dr. Chin has served as the Clinical Director of Nuclear Medicine at Johns Hopkins, and approaches imaging research from the translational perspective. He has published numerous manuscripts in oncologic PET, and has served as Principal Investigator on several projects including federally funded grants. He is currently focused on translational aspects of PET imaging in oncology with a concentration in genitourinary cancers.

)

Duke University Medical Center
Durham, NC
USA

D. Denoyer
Peter MacCallum Cancer Centre
Melbourne
Australia

M. Farsad
San Maurizio Hospital
Bolzano
Italy

A. Gee
GSK & Hammersmith Hospital
London
UK

B. Guérin (Biography
B. Guérin

Brigitte Guérin is Full Professor in the Department of Nuclear Medicine & Radiobiology of the Université de Sherbrooke, Head of the Radiochemistry Laboratory of the Molecular Imaging Centre of Sherbrooke (CIMS) and she holds Jeanne and J.-Louis Lévesque Chair in Radiobiology. Her in-depth knowledge of the peptide synthetic chemistry opens a new avenue of research for the development of radiopharmaceuticals, multimodal probes for several medical conditions. Her research interests include the development of radioisotopes and on the design, synthesis and preclinical validation of radiotracers, radiotheranostics and multimodal probes targeting overexpressed biomarkers in various cancers for molecular imaging and targeted therapy.

)

Université de Sherbrooke
Sherbrooke, QC
Canada

J.Z. Ho
Merck & Co., Inc.
New Jersey, NJ
USA

S.J. Hughes
Royal Victoria Hospital
Belfast, Northern Ireland
UK

A.I. Kassis (Biography
A.I. Kassis

Amin I. Kassis, PhD, is a world expert in the therapeutic effects of cancer-targeting radioactive agents and a prolific inventor. At Harvard Medical School and the Brigham and Women’s Hospital, Professor Kassis has been the Director of the Radiobiology and Experimental Radionuclide Therapy Section. Several biomedical technologies invented by Professor Kassis are being developed by startup corporations that he founded/co-founded: (i) OncoTherapeutica, Inc., a NewCo committed to curing solid tumors, and (ii) OncoCell MDx, Inc., a biotechnology company assessing the ability of blood-based genomic assays for discriminating lethal from nonlethal prostate cancer.

)

Harvard Medical School
Boston, MA
USA

J. Knuuti (Biography
J. Knuuti

His main research field is noninvasive imaging especially using PET, SPECT, echocardiography, MRI and CT. He has published nearly 500 articles in peer reviewed journals and books and has contributed to large number clinical guidelines. The main research focus has been on cardiovascular diseases especially coronary artery disease and heart failure. He works actively in European Society of Cardiology, European Association of Nuclear Medicine and European Society for Molecular Imaging in the working groups, councils and guidelines committees. He has arranged several international congresses and acts as member of editorial boards of several scientific journals. He is currently also Senior Associate Editor of European Heart Journal – Cardiovascular Imaging.

)

Turku PET Centre
Turku
Finland

R.H. Larsen (Biography
R.H. Larsen

Dr. Roy H. Larsen has a Ph.D. and postdoctoral experience in radiopharmaceutical chemistry from University of Oslo, Norway and Duke University, USA, respectively. Dr. Larsen was the main inventor in and founder of Algeta ASA (founded in 1997, acquired by Bayer AG in 2014), and he served as Managing Director and later Chief Scientific Officer in Algeta ASA from 1997-2006, He was a inventor in and founder of Nordic Nanovector ASA (2009), and Oncoinvent AS (2010). Dr. Larsen works as a consultant, inventor, founder etc within the field of radionuclide based therapeutics. Currently affiliated with Oncoinvent AS, Oslo, Norway.

)

The Norwegian Radium Hospital
Oslo
Norway

J. Lin (Biography
J. Lin

Dr. Jianguo Lin obtained his doctorate (Ph.D.) in Chemistry from the Nanjing University, China. As a visiting scholar, he studied for one year at Molecular Imaging Program of Stanford University. Currently Dr. Lin is an associated professor and director of research group at Jiangsu Institute of Nuclear Medicine (China). His research interest mainly focus on the development of radiolabled imaging probes (PET/SPECT) of tumors. He has published more than 50 scientific publications and is a named inventor of 5 issued Chinese patents.

)

Jiangsu Institute of Nuclear Medicine
Wuxi
China

P. Mapelli
IRCCS San Raffaele Scientific Institute
Milan
Italy

C. Nanni
Azienda Ospedaliero-Universitaria di Bologna Policlinico S.Orsola-Malpighi
Bologna
Italy

M.R.A. Pillai
Bhabha Atomic Research Centre
Mumbai
India

P.F. Rambaldi
Second University of Naples
Naples
Italy

H. Saji
Kyoto University
Kyoto
Japan

S. Sestini (Biography
S. Sestini

Born in Florence, November 25, 1966. Nuclear Medicine Doctor, level B1 (D. Lgs 229/99, Deliberazione n. 766/25.05.2001) Co-Chief, Nuclear Medicine Unit, PET Center, Dept. of Diagnostic Imaging, NOP S. Stefano Hospital, Prato (Italy). MD at University of Florence and PhD in Functional Neuroimaging at University of Florence (Italy)/ Karolinska Institute Dept. of Neuroscience, Stockholm (Sweden), has a long experience in the field of Nuclear Medicine, with particular attention to bio-molecular neuro-imaging of brain and myocardium. From 2004 is appointed as Professor of Nuclear Medicine at University of Florence. Author of several full articles published in peer reviewed international journals (Medline), chapters and books; invited lecturer in national and international meetings.

)

Nuclear Medicine Unit, NOP S. Stefano
Prato
Italy

M. Sperrin
Royal Berkshire Hospital
Reading
UK

G. Tang
Xi'an Jiaotong University
Xi'an
China

G. Vaidyanathan (Biography
G. Vaidyanathan

Ganesan Vaidyanathan received his B.Sc (1973) and M.Sc (1975) in Chemistry from the University of Calicut, India and Ph.D. in Organic Chemistry from the University of Kentucky (1987). Since 1989 he is working in the Nuclear Medicine division, Department of Radiology, Duke University Medical Center, Durham, North Carolina, USA. He is also a faculty of the Medical Physics Graduate Program at Duke. His research interests include the development of 18F-, radioiodine-, 211At-, and 177Lu-labeled radiopharmaceuticals for cancer diagnosis and therapy. He has 105 peer-reviewed publications to his credit.

)

Duke University Medical Center
Durham, NC
USA

T. Wirth
Cardiff University
Cardiff
UK












Advertisement

Related Journals





Webmaster Contact: info@benthamscience.org Copyright © 2017 Bentham Science